Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial.
Jonathan M LoreeEmma TitmussJames T TophamHagen F KenneckeHarriet E FeilotterShakeel VirkYoung S LeeKimberly C BanksKatie QuinnAly KarsanDaniel J RenoufDerek J JonkerDongsheng TuChris J O'CallaghanEric X ChenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
pTMB derived from either clonal or subclonal mutations may identify a group likely to benefit from immunotherapy, although validation is required. Tissue TMB provided no predictive utility for immunotherapy in this trial.